Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
27 studies found for:    "gene therapy" OR "gene transfer" OR "virus delivery" | HIV
Show Display Options
Rank Status Study
1 Unknown  Gene Therapy With GX-12 in Combination With HAART for the HIV-1 Infected Patients
Condition: HIV Infections
Interventions: Genetic: GX-12;   Drug: HAART
2 Terminated Setting up a Blood Bank for Gene Therapy in HIV-Infected Infants
Conditions: HIV Infections;   Pregnancy
Intervention:
3 Active, not recruiting Safety Study of a Dual Anti-HIV Gene Transfer Construct to Treat HIV-1 Infection
Condition: Human Immunodeficiency Virus
Interventions: Drug: Busulfan;   Biological: Cal-1 modified HSPC;   Biological: Cal-1 modified CD4+ T lymphocytes
4 Completed Redirected High Affinity Gag‐Specific Autologous T Cells for HIV Gene Therapy
Condition: HIV Infections
Interventions: Biological: WT-gag-TCR modified T cells;   Biological: α/6-gag-TCR modified T cells;   Other: STI or Drug Holiday
5 Terminated Gene Transfer for HIV Using Autologous T Cells
Condition: HIV-1 Infection
Intervention: Genetic: pHIV7-shI-TAR-CCR5RZ treated CD4 cells
6 Completed Twins Study of Gene Therapy for HIV Infection
Conditions: Acquired Immunodeficiency Syndrome;   HIV Infection;   Kaposi's Sarcoma
Intervention: Drug: Syngeneic Lymphocytes (CD4+) Cultured with OKT3 (Ortho) and Interleukin-2 (Chiro
7 Completed Gene Therapy in HIV-Positive Patients With Non-Hodgkin's Lymphoma
Conditions: Lymphoma, Non-Hodgkin;   HIV Infections
Intervention: Drug: Peripheral blood stem cells
8 Active, not recruiting Long Term Follow-Up Study of Human Immunodeficiency Virus Type 1 (HIV-1) Positive Patients Who Have Received OZ1 Gene Therapy as Part of a Clinical Trial
Condition: HIV-1
Intervention: Genetic: OZ1 transduced cells
9 Active, not recruiting Safety and Efficacy of T Cell Genetic Immunotherapy for HIV
Condition: HIV Infection
Intervention: Genetic: VRX496-Modified Autologous T cells
10 Active, not recruiting Redirected MazF‐CD4 Autologous T Cells for HIV Gene Therapy
Condition: HIV
Intervention: Genetic: Autologous CD4+ T cells genetically modified with a retroviral vector expressing the MazF endoribonuclease gene (MazF‐T), given via intravenous infusion.
11 Recruiting Gene Therapy in Treating Patients With Human Immunodeficiency Virus-Related Lymphoma Receiving Stem Cell Transplant
Conditions: HIV Infection;   Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma;   Plasmablastic Lymphoma;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Non-Hodgkin Lymphoma;   Recurrent Burkitt Lymphoma;   Recurrent Follicular Lymphoma;   Stage III Follicular Lymphoma;   Stage III Mantle Cell Lymphoma;   Stage IV Follicular Lymphoma;   Stage IV Mantle Cell Lymphoma
Interventions: Procedure: Autologous Hematopoietic Stem Cell Transplantation;   Drug: Carmustine;   Drug: Cytarabine;   Drug: Etoposide;   Other: Laboratory Biomarker Analysis;   Biological: Lentivirus Vector CCR5 shRNA/TRIM5alpha/TAR Decoy-transduced Autologous CD34-positive Hematopoietic Progenitor Cells;   Drug: Melphalan;   Procedure: Peripheral Blood Stem Cell Transplantation
12 Recruiting Gene Therapy After Frontline Chemotherapy in Treating Patients With AIDS-Related Non-Hodgkin Lymphoma
Conditions: AIDS-related Non-Hodgkin Lymphoma;   AIDS-related Plasmablastic Lymphoma;   AIDS-related Primary Effusion Lymphoma;   HIV Infection
Interventions: Drug: busulfan;   Biological: lentivirus vector rHIV7-shI-TAR-CCR5RZ-transduced hematopoietic progenitor cells;   Other: pharmacological study;   Other: laboratory biomarker analysis
13 Completed Genetically Modified Lymphocytes to Treat HIV-Infected Identical Twins - Study Modifications
Conditions: Acquired Immunodeficiency Syndrome;   HIV Infection
Intervention: Drug: Interleukin-2
14 Withdrawn Oral Auranofin for Reduction of Latent Viral Reservoir in Patients With HIV Infection
Condition: HIV
Intervention: Drug: Auranofin
15 Completed An Efficacy and Safety Study of Autologous Cluster of Differentiation 34 (CD34+) Hematopoietic Progenitor Cells Transduced With Placebo or an Anti- Human Immunodeficiency Virus Type 1 (HIV-1) Ribozyme (OZ1) in Participants With HIV-1 Infection
Condition: HIV-1
Interventions: Other: Placebo;   Genetic: OZ1;   Genetic: CD34+ cells
16 Recruiting Gene Therapy and Combination Chemotherapy in Treating Patients With AIDS-Related Non-Hodgkin Lymphoma
Conditions: AIDS-Related Burkitt Lymphoma;   AIDS-Related Diffuse Large B-cell Lymphoma;   AIDS-Related Plasmablastic Lymphoma;   AIDS-Related Primary Effusion Lymphoma;   HIV Infection;   AIDS Related Non-Hodgkin Lymphoma
Interventions: Drug: Prednisone;   Biological: Rituximab;   Drug: Etoposide;   Drug: Doxorubicin Hydrochloride;   Drug: Vincristine Sulfate;   Drug: Cyclophosphamide;   Biological: Filgrastim;   Biological: Lentivirus Vector rHIV7-shI-TAR-CCR5RZ-transduced Hematopoietic Stem/Progenitor Cells
17 Suspended Gene-Modified HIV-Protected Stem Cell Transplant in Treating Patients With HIV-Associated Lymphoma
Conditions: AIDS-Related Hodgkin Lymphoma;   AIDS-Related Non-Hodgkin Lymphoma;   HIV Infection;   Recurrent Hodgkin Lymphoma;   Recurrent Non-Hodgkin Lymphoma
Interventions: Biological: Gene-Modified HIV-Protected Hematopoietic Stem Cells;   Other: Laboratory Biomarker Analysis;   Other: Transplant Conditioning
18 Completed Stem Cell (Modified Bone Marrow) Transplantation in HIV-Infected Patients With Blood Cancer
Conditions: Hematologic Neoplasm;   HIV Infection
Intervention: Drug: GCSF Mobilized Allogeneic PBSC Cultured w/Cytokines; Transduced w/RV
19 Enrolling by invitation Long Term Follow up for the Detection of Delayed Adverse Events in Cal-1 Recipients
Conditions: HIV-1 Infection;   Receipt of Cal-1 Modified Hematopoietic Cellular Products
Intervention: Genetic: Blood tests
20 Withdrawn Genetically Modified Peripheral Blood Stem Cell Transplant in Treating Patients With HIV-Associated Non-Hodgkin or Hodgkin Lymphoma
Conditions: Adult Nasal Type Extranodal NK/T-cell Lymphoma;   AIDS-related Diffuse Large Cell Lymphoma;   AIDS-related Diffuse Mixed Cell Lymphoma;   AIDS-related Diffuse Small Cleaved Cell Lymphoma;   AIDS-related Immunoblastic Large Cell Lymphoma;   AIDS-related Lymphoblastic Lymphoma;   AIDS-related Peripheral/Systemic Lymphoma;   AIDS-related Small Noncleaved Cell Lymphoma;   Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-cell Lymphoma;   Cutaneous B-cell Non-Hodgkin Lymphoma;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Hepatosplenic T-cell Lymphoma;   HIV-associated Hodgkin Lymphoma;   Intraocular Lymphoma;   Nodal Marginal Zone B-cell Lymphoma;   Noncutaneous Extranodal Lymphoma;   Peripheral T-cell Lymphoma;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Adult T-cell Leukemia/Lymphoma;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Small Lymphocytic Lymphoma;   Refractory Hairy Cell Leukemia;   Small Intestine Lymphoma;   Splenic Marginal Zone Lymphoma;   Stage I AIDS-related Lymphoma;   Stage II AIDS-related Lymphoma;   Stage III AIDS-related Lymphoma;   Stage IV AIDS-related Lymphoma;   T-cell Large Granular Lymphocyte Leukemia;   Testicular Lymphoma;   Waldenström Macroglobulinemia
Interventions: Drug: carmustine;   Drug: cytarabine;   Drug: melphalan;   Drug: etoposide;   Drug: O6-benzylguanine;   Procedure: autologous hematopoietic stem cell transplantation;   Procedure: peripheral blood stem cell transplantation;   Other: laboratory biomarker analysis

   Previous Page Studies Shown (1-20) Next Page (21-27) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.